Announcements Trials
Browse Landscape

Phase

Phase 2 72Phase 1 39Phase 1/2 32Phase 3 16Phase EARLY_PHASE1 4Phase 4 3Phase 2/3 3Phase NA 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × ruxolitinib × Clear all
NCT04744116 2026-05-05

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
24 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Baylor Research Institute

Phase EARLY_PHASE1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06209606 2024-12-17

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Oncotherapeutics

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT02593929 2017-06-08

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

University of Pittsburgh

Phase EARLY_PHASE1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡